Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy
Open accessThe DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1) receptor agonists are established pharmaceutical therapies for the treatment of type 2 diabetes and obesity. They mimic the action of GLP-1 to reduce glucose levels through stimulation of insulin secretion and inhibition of glucagon secretion. They also reduce body weight by inducing satiety through central actions. The GLP-1 receptor agonists used clinically are based on exendin-4 and native GLP-1 and are available as formulations for daily or weekly s.c. or oral administration. GLP-1 receptor agonism is also achieved by inhibitors of dipeptidyl peptidase-4 (DPP-4), which prevent the inactivation of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), thereby prolonging their raised levels after meal ingestion. Other developments in GLP-1 receptor agonism include the formation of small orally available agonists and compounds with the potential to pharmaceutically stimulate GLP-1 secretion from the gut. In addition, GLP-1/glucagon and GLP-1/GIP dual receptor agonists and GLP-1/GIP/glucagon triple receptor agonists have shown the potential to reduce blood glucose levels and body weight through their effects on islets and peripheral tissues, improving beta cell function and stimulating energy expenditure. This review summarises developments in gut hormone-based therapies and presents the future outlook for their use in type 2 diabetes and obesity. Graphical Abstract
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Fig. 3 Structures of formulations of GLP-1 receptor agonists [14, 15, 19–21, 26]. (a) GLP-1, (b) exenatide, (c) lixisenatide, (d) efpeglenatide, (e) liraglutide, (f) semaglutide, (g) dulaglutide, (h) albiglutide. Amino acids are illustrated in circles; red circles show amino acids that are different from those in GLP-1. The red arrow in (a) illustrates the site of DPP-4 inactivation. This figure is available as part of a downloadable slideset](https://figures.cochat.ai/paper-figures/ccfebf3c711343c5a6b540b87c7f92a1/gut-hormone-based-pharmacology-novel-formulations-and-future-possibilities-for-figure-3.jpg)
![Fig. 4 Structures of (a) GLP-1, (b) GIP and (c) tirzepatide [19, 88, 90]. Amino acids are illustrated in circles; blue circles show amino acids that are identical to those in GLP-1; black circles show amino acids that are present in GIP and tirzepatide but not in GLP-1; red circles show amino acids that are identical in tirzepatide and exenatide (see Fig. 3b); and green circles show amino acids that are present in tirzepatide but not in GLP-1, GIP or exenatide. AiB, aminoisobutyric acid. This figure is available as part of a downloadable slideset](https://figures.cochat.ai/paper-figures/811627b60550401f876ddf858a6b6b85/gut-hormone-based-pharmacology-novel-formulations-and-future-possibilities-for-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Regarding triple GIPR/GLP-1R/GCGR agonists such as retatrutide, the inclusion of a GCGR moiety may seem counter intuitive given that a key action of GCG is to raise blood glucose by increasing hepatic glucose output [14].”
From Recent advances in peptide-based therapies for obesity and type 2 diabetes (2024) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“the dual action on GIP and GLP-1 receptors may confer additive or synergistic effects on glycemic control and appetite regulation, leading to greater weight reductions [59].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868 · cited 4×
“GLP-1 is a 30 amino acid peptide that is produced by and released from intestinal L cells after meal ingestion and which in turn stimulates insulin secretion [5].”
BackgroundInfluentialSelf-citationSattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048 · cited 3×
“Hence, in 2022, glucose-lowering efficacy and proven cardiovascular effects were important for the strong positioning of semaglutide, dulaglutide and tirzepatide in guidelines on the management of hyperglycaemia in type 2 diabetes [33], and a similar strong positioning of incretin therapy was seen in guidelines on pri…”
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 1×
“Consistent with this, whole-body GIP receptor deficiency and GIP deficiency protect against obesity induced by long-term high fat feeding in mice [65, 66].”
BackgroundCoskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882 · cited 3×
“4 Structures of (a) GLP-1, (b) GIP and (c) tirzepatide [19, 88, 90].”
BackgroundGutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Göke, R., Fehmann, H. C., Linn, T., Schmidt, H., Krause, M., Eng, J., & Göke, B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36565-2 · Cited by 837 · cited 1×
“1 3 was isolated from venom produced by the perimandibular glands of the Gila monster (Heloderma suspectum) [18].”
Background
Research works printed but not linked: 1
- Ahrén B (2001) Inhibition of dipeptidyl peptidase-4 (DPP-4): a target to treat type 2 diabetes. Curr Enzyme Inh 7:206–217
Cited by
Enteroendocrine cell regulation of the gut-brain axis
Barton, J. R., Londregan, A., Alexander, T. D., Entezari, A. A., Covarrubias, M., & Waldman, S. A. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1272955 · Cited by 102
“Recently, they have come into the spotlight after the recent success of GLP-1 receptor agonists, glucagon analogues, and GIP analogues (Tschöp et al., 2023).”
BackgroundManaging insulin resistance: the forgotten pathophysiological component of type 2 diabetes
Abdul-Ghani, M. A., Maffei, P., & DeFronzo, R. A. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00127-x · Cited by 89
Gigliotti, L., Warshaw, H., Evert, A., Dawkins, C., Schwartz, J., Susie, C., Kushner, R., Subramanian, S., Handu, D., & Rozga, M. (2025) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2024.10.023 · Cited by 53
Sztanek, F., Tóth, L. I., Pető, A., Hernyák, M., Diószegi, Á., & Harangi, M. (2024) · Biomedicines · doi:10.3390/biomedicines12061320 · Cited by 47
“Figure 1 schematically depicts the incretin-based agents that are currently used in everyday medical practice or that are currently under clinical development [9].”
BackgroundInfluentialJakubowska, A., Roux, C. W. L., & Viljoen, A. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1942 · Cited by 45
“Further GIP receptors are in the central nervous system including the hypothalamus, hippocampus, cerebral cortex, and olfactory bulb [20].”
BackgroundInfluentialHuang, Y., Liao, W., Huang, J., Lin, Y., Yang, S., Huang, C., Wang, C., & Su, P. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15869 · Cited by 44
Merovci, A., Finley, B., HANSIS-DIARTE, A. A., Neppala, S., Abdul‐Ghani, M. A., Cersósimo, E., Triplitt, C. L., & DeFronzo, R. A. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004199 · Cited by 40
Stefanou, M.-I., Palaiodimou, L., Theodorou, A., Safouris, A., Fischer, U., Kelly, P. J., Dawson, J., Katan, M., Katsanos, A. H., Lambadiari, V., et al. (2024) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864241281903 · Cited by 36
“10 13 Importantly, meta-analyses of RCTs have established that GLP-1 RAs exert highly potent glucose-regulating effects in T2DM, significantly reducing hemoglobin A1c (HbA1c) levels and body weight in a dose-dependent manner compared to placebo.”
BackgroundObesity and the gut microbiota: implications of neuroendocrine and immune signaling
Romaní‐Pérez, M., Liébana-García, R., Flor‐Duro, A., Bonillo‐Jiménez, D., Bullich‐Vilarrubias, C., Olivares, M., & Sanz, Y. (2024) · FEBS Journal · doi:10.1111/febs.17249 · Cited by 37
“Currently, different GLP-1 based drugs have been developed with different efficacies and routes of administration [149] with some of them recently approved for chronic weight control, such as liraglutide and semaglutide [35].”
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2025) · Peptides · doi:10.1016/j.peptides.2025.171380 · Cited by 40
“Although GCGRA activity may seem counterintuitive (discussed earlier, Section 3), it is relevant to note here that GCGRAs reduce appetite and increase energy consumption, thereby giving additive weight-lowering efficacy [1 – 4].”
Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
Son, J. W., & Lim, S. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1940 · Cited by 33
“2 [36].”
Incretins and cardiovascular disease: to the heart of type 2 diabetes?
Solini, A., Tricò, D., & Del Prato, S. (2023) · Diabetologia · doi:10.1007/s00125-023-05973-w · Cited by 32
“Glucagon has always been considered a main player in diabetes, as a counterregulatory hormone, although some interest was transiently generated because of its inotropic and chronotropic action [16].”
BackgroundThe interplay of glucose-dependent insulinotropic polypeptide in adipose tissue
Kagdi, S., Lyons, S. A., & Beaudry, J. L. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0361 · Cited by 33
“However, it is important to note that disruption in GIP signaling observed in individuals with T2DM is linked with increasing measurements of body mass index (reviewed in Finan et al. (2016)).”
BackgroundInfluentialNon-canonical G protein signaling
Nürnberg, B., Beer‐Hammer, S., Reisinger, E., & Leiss, V. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108589 · Cited by 30
Peptide GLP-1 receptor agonists: From injection to oral delivery strategies
Ke, Z., Ma, Q., Ye, X., Wang, Y., Jin, Y., Zhao, X., & Su, Z. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116471 · Cited by 28
Johnson, H., Huang, D., Liu, V., Ammouri, M. A., Jacobs, C., & El-Osta, A. (2025) · Journal of Medical Internet Research · doi:10.2196/69466 · Cited by 27
Recent advances in peptide-based therapies for obesity and type 2 diabetes
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2024) · Peptides · doi:10.1016/j.peptides.2024.171149 · Cited by 25
Seeking satiety: From signals to solutions
Tschöp, M. H., & Friedman, J. M. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh4453 · Cited by 30
“Semaglu-tide, an optimized derivative of GLP-1, has shown substantial efficacy for the treatment of obesity, and newer molecules with agonist activity at multiple receptors are even more potent, as discussed below ( 18 ).”
BackgroundSelf-citationGIP attenuates neuronal oxidative stress by regulating glucose uptake in spinal cord injury of rat
Guo, B., Qi, M., Luo, X., Guo, L., Xu, M., Zhang, Y., Li, Z., Li, M., Wu, R., Guan, T., et al. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14806 · Cited by 24
“23 Then, we used the modified GIP (D-Ala 2 GIP) that substituted the left-handed Ala with right-handed Ala for the experiment of spinal cord injury, which acts as a GIPR agonist with a long half-life in vivo.”
MethodInsights into the Mechanism of Action of Tirzepatide: A Narrative Review
Galindo, R. J., CHENG, A. Y. Y., Longuet, C., Ai, M., Coşkun, T., Malik, R., Peleshok, J. C., Levine, J. A., & Dunn, J. P. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01804-w · Cited by 32
“The GLP-1R is expressed in various tissues, including but not limited to pancreatic β -cells, various cell types of the gastrointestinal tract, neurons throughout the peripheral and central nervous system (CNS), the kidney, the vasculature, and the heart [8–10].”
Emerging role of antidiabetic drugs in cardiorenal protection
Fu, W.-J., Huo, J., Mao, Z., Pan, S.-K., Liu, D., Liu, Z., Wu, P., & Gao, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1349069 · Cited by 24
Pepa, G. D., Patrício, B. G., Carli, F., Sabatini, S., Astiarraga, B., Ferrannini, E., Camastra, S., & Gastaldelli, A. (2024) · Diabetes · doi:10.2337/db23-0972 · Cited by 21
Incretins and the cardiovascular system: bridging digestion with metabolism
Avogaro, A., & Fadini, G. P. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00166-4 · Cited by 21
Pharmacotherapy for Obesity: Recent Updates
Fredrick, T. W., Camilleri, M., & Acosta, A. J. (2025) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s497904 · Cited by 33
Unraveling the complexities of diet induced obesity and glucolipid dysfunction in metabolic syndrome
Dutta, B., Tripathy, A., Archana, P. R., & Kamath, S. U. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01837-y · Cited by 20
Weight Loss Interventions for Adults With Obesity-Related Asthma
Foer, D., Forno, E., Holguín, F., & Cahill, K. N. (2023) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2023.12.041 · Cited by 19
Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges
Allard, C., Cota, D., & Quarta, C. (2023) · Drugs · doi:10.1007/s40265-023-01982-6 · Cited by 17
“In addition, injecting multiple pharmacological species requires full clinical development of each molecular component, dramatically increasing production costs and delaying translation from bench to bedside [7, 8].”
GLP-1, GIP, and Glucagon Agonists for Obesity Treatment: A Hunger Perspective
d’Ávila, M., Hall, S., & Horváth, T. L. (2024) · Endocrinology · doi:10.1210/endocr/bqae128 · Cited by 14
Advances in Oral Biomacromolecule Therapies for Metabolic Diseases
Jiao, Q., Huang, Y., He, J., & Xu, Y. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17020238 · Cited by 13
“Several gut hormonal-based pharmacotherapies targeting energy expenditure are currently being explored and developed [322–324].”
Advances in obesity pharmacotherapy; learning from metabolic surgery and beyond
Tsilingiris, D., & Kokkinos, A. D. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155741 · Cited by 16
Lin, Y., Xu, G., Li, L., Xiang, J., & Zhai, L. (2024) · Medicine · doi:10.1097/md.0000000000038018 · Cited by 12
“[8,9] Thus, incretin-based drugs have like-wise received some attention for their association with PCa risk.”
BackgroundWang, S., Shi, Y., Xin, R., Kang, H., Xiong, H., & Ren, J. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1614006 · Cited by 16
“Glucagon-like peptide-1 (GLP-1) receptor agonists are standard therapies for type 2 diabetes and obesity, lowering blood glucose and body weight by promoting insulin secretion, inhibiting glucagon release, and inducing satiety via central nervous system actions (196).”
Glucokinase activators and imeglimin: new weaponry in the armamentarium against type 2 diabetes
Sjöholm, Å. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004291 · Cited by 10
Kowalska, M. K., El‐Mallul, A., Hudecka, W., Lubojańska, J. E., Lubojański, P. J., Orłowska, S. M., & Bednarczyk, Ł. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27041886 · Cited by 9
Bain, S. C., & Min, T. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01182-0 · Cited by 9
Old and new anti-obesity drugs
Dodangeh, S., & Hasani‐Ranjbar, S. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01512-5 · Cited by 8
“These characteristics support the use of glucagon in combination with other gastrointestinal hormones that have opposite glucose-lowering effects for the treatment of obesity and T2DM [68].”
Pacini, G., & Åhrén, B. (2023) · Peptides · doi:10.1016/j.peptides.2023.171117 · Cited by 8
Paradigm Shift in the Management of Metabolic Diseases—Next-Generation Incretin Therapy
Åhrén, B. (2023) · Endocrinology · doi:10.1210/endocr/bqad166 · Cited by 8
Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2026) · Peptides · doi:10.1016/j.peptides.2026.171480 · Cited by 7
Incretin mimetics for the management of diabetes and associated comorbidities: An overview
Haider, F., Imam, S., Tulp, O. L., & Rizvi, S. A. A. (2024) · Innovative Medicines & Omics · doi:10.36922/imo.4911 · Cited by 7
Incretins: turning the venom into the antidote
Krook, A., & Mulder, H. (2023) · Diabetologia · doi:10.1007/s00125-023-05987-4 · Cited by 7
Shirani, A., & Stüve, O. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2587277 · Cited by 7
“Beyond glycemic control, GLP-1RAs have demonstrated significant benefits in weight reduction, leading to their approval for obesity management at higher doses (e.g. liraglutide 3 mg daily, semaglutide 2.4 mg weekly) [53,59].”
InfluentialEmerging Therapies in Metabolic Health: A Comprehensive Review of GLP‐1, GIP, and Glucagon Agonists
Khan, M. S., Bhutani, U., Venugopal, H., Saini, A. K., Naidu, V. R., & Kollipara, S. (2026) · Journal of Peptide Science · doi:10.1002/psc.70083 · Cited by 7
Obesity-driven hunger: From pathophysiology to intervention
Azemi, A. K., Mutalub, Y. B., Abdulwahab, M., Rasool, A. H. G., Mustapha, S., Suhaimi, S. Q. A., & Mokhtar, S. S. (2025) · Obesity Medicine · doi:10.1016/j.obmed.2025.100588 · Cited by 8
Duodenal enteroendocrine cells and GIP as treatment targets for obesity and type 2 diabetes
Bailey, C. J., & Flatt, P. R. (2024) · Peptides · doi:10.1016/j.peptides.2024.171168 · Cited by 6
Fragozo-Ramos, M. C., Schenker, G., Hepprich, M., Gallo‐Villegas, J., Züger, T., & Garcia‐Tirado, J. (2025) · PLoS ONE · doi:10.1371/journal.pone.0335060 · Cited by 6
“Additionally, GLP-1RAs and GIP/GLP-1RAs induce early, acute changes in appetite and satiety, leading to reduced caloric intake and weight loss [27,28] .”
Are GLP-1 receptor agonists and diabetic retinopathy foes or friends?
Liu, K., Liu, S., Wang, D., & Qiao, H. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101696 · Cited by 6
The sex and reproductive plasticity of intestinal muscles instruct gut size
Mineo, A., Blackie, L., Milona, A., Strachan, E., Gaspar, P., Luis, N. M., Castano-Medina, A., Ameku, T., Silva, B., Prasad, A. R., et al. (2026) · Cell · doi:10.1016/j.cell.2026.07.024 · Cited by 5
Bloomgarden, Z. T. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13434 · Cited by 5
Donado-Pestana, C. M., Vasconcelos, A. D., Mantovam, V. B., de Lima, G. C., Rodrigues, L., Barbeiro, H. V., Fock, R. A., de Souza, H. P., Franco, B. D. G. D. M., & Fiamoncini, J. (2025) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2025.109958 · Cited by 4
Zhao, X., Cheng, Y., Xu, J., & Cui, C. (2025) · Food Chemistry · doi:10.1016/j.foodchem.2025.144725 · Cited by 4
Gryglewska-Wawrzak, K., Kapłon‐Cieślicka, A., Pawlak, A., Tomaszuk−Kazberuk, A., Rubiś, P., Niedziela, J. T., & Bielecka-Dabrowa, A. M. (2025) · Pharmaceuticals · doi:10.3390/ph18111726 · Cited by 4
“These pharmacological agents are designed to mimic native GLP-1 but have enhanced stability and bioactivity, thereby prolonging their therapeutic effects [48].”
Chartoumpekis, D. V., Chen, I., Salvatore, S. R., Schopfer, F. J., Freeman, B. Α., & Khoo, N. K. H. (2024) · Nitric Oxide · doi:10.1016/j.niox.2024.06.002 · Cited by 4
“…incretin-based therapies for obesity, including glucagon-like-peptide-1 (GLP-1) and GLP1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, which were originally designed for diabetes treatment, the landscape of medical approaches to obesity has shifted in everyday practice [57].”
Lee, J., Ko, S., Choi, N. R., Choi, W.-G., Seo, M., Koo, S. H., Jung, D.-H., Lee, M. J., Lee, J. H., Park, J.-W., et al. (2024) · International Journal of Medical Sciences · doi:10.7150/ijms.103507 · Cited by 4
Smits, M. M., Christensen, L. V. V., Drzazga, A. K., Beaman, E. E., Brethvad, A. O., Holst, J. J., & ROSENKILDE, M. M. (2024) · Food Chemistry · doi:10.1016/j.foodchem.2024.140759 · Cited by 3
Portha, B., Liu, J., Movassat, J., & Tourrel‐Cuzin, C. (2024) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2024.09.003 · Cited by 3
Positron emission tomography to assess drug occupancy at peripheral and central incretin receptors
Khalil, A., Velikyan, I., Xiong, M., Bossart, M., Wagner, M., & Eriksson, O. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.106033 · Cited by 3
Pharmacological interactions between asthma and T2DM therapies: clinical and metabolic implications
Matera, M. G., Page, C. P., Calzetta, L., Rogliani, P., & Cazzola, M. (2026) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2026.2632668 · Cited by 3
“GLP-1 receptor agonists (GLP-1RAs) mimic endogenous GLP-1 by enhancing glucose-dependent insulin secretion from β-cells, suppressing glucagon release from α-cells, slowing gastric emptying, and promoting central satiety, thereby improving glycemic control and inducing weight loss [139,140].”
Meza, A. D. V., Nocek, M. J., Mitchell, B. C., Lizarraga, M. A., DeFoor, M. T., Ruzbarsky, J. J., Huard, J., & Philippon, M. J. (2026) · JBJS Reviews · doi:10.2106/jbjs.rvw.26.00027 · Cited by 3
Prise en charge pharmacologique de l’obésité : l’apport des nouvelles classes médicamenteuses
Bauduceau, B., Bordier, L., Schlienger, J.-L., & Monnier, L. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.11.008 · Cited by 3
Winther‐Sørensen, M., Rasmussen, C. B., Trammell, S. A. J., Hansen, C., Vyberg, M., Serizawa, R., Richter, E. A., Grevengoed, T. J., Gluud, L. L., Kuhre, R. E., et al. (2025) · Peptides · doi:10.1016/j.peptides.2025.171462 · Cited by 2
Glucagon-Like Peptide-1 Receptor Agonists: Their Potential Role in Prediabetes
Panou, T., Gouveri, E., Popovic, D. S., Papazoglou, D., & Παπάνας, Ν. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01865-5 · Cited by 2
“The therapeutic armamentarium of GLP-1RAs is constantly expanding [72].”
Anesto, J. B., Dotres, K., & Nicolau, J. (2026) · Nutrición Hospitalaria · doi:10.20960/nh.06592 · Cited by 2
Cardiorenal effects of therapies for type 2 diabetes and obesity
Bailey, C. J., & Day, C. (2024) · British Journal of Cardiology · doi:10.5837/bjc.2024.041 · Cited by 2
Frey, S., Louis-Gaubert, C., Thouzeau, A., Cossé, L., Lorant, V., Prieur, X., Flet, L., Cariou, B., Blanchard, C. L., & May, C. L. (2025) · Obesity · doi:10.1002/oby.70003 · Cited by 2
Parichehreh, E., Kiaei, A. A., Boush, M., Safaei, D., Bahadori, R., Salari, N., Mohammadi, M., & Khorram, A. (2024) · medRxiv · doi:10.1101/2024.02.18.24302988 · Cited by 6
“[91], [92], [93] Azaserine, a serine derivative diazo compound found in nature, possesses both properties that act against both cancerous cells and bacteria.”
Incretins and the metabolic syndrome
Karásek, D. (2024) · Vnitřní lékařství · doi:10.36290/vnl.2024.020 · Cited by 1
Portha, B., Liu, J., Movassat, J., & Tourrel‐Cuzin, C. (2025) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2025.05.006 · Cited by 1
Choudhury, A., Kodra, J. D., Mathson, L., Hanley, J., LoGiudice, A. J., & Sullivan, C. W. (2026) · Hand · doi:10.1177/15589447261451445 · Cited by 1
GLP-1 Receptor Agonists in Neurological Disorders: From Mechanisms to Clinical Translation
Li, P., Gao, Y., & (20030), W. L. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s613616 · Cited by 2
“15 These drugs were first made for type 2 diabetes, and later they got approved for obesity because they help people lose weight.”
Fan, Y., Chen, X., Cai, X., Dong, Y., Liu, C., Chen, Y., Lip, G. Y. H., & Zhu, W. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156678 · Cited by 1
Ying, H., Wang, Q., He, Q., Cao, Y., Wei, G., Xiao, Z., & Luo, X. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1834999 · Cited by 2
“Additionally, such circadian disruption impairs the suppression of glucagon secretion, thereby exacerbating nocturnal gluconeogenesis (Tschöp et al., 2023).”
Caspi, A., Khazanov, N., Helman, A., Lankry, H., Levavi‐Sivan, B., Senderowitz, H., & Kerem, Z. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27125630 · Cited by 1
“Further, newly published analyses underscore the colonic GLP-1/GLP-1R axis as a promising pharmacological target, with potential for both therapeutic intervention and prevention strategies in diabetes management [18,19].”
BEYOND BLOOD SUGAR CONTROL: A COMPREHENSIVE REVIEW OF DPP-4 INHIBITORS AND THEIR EXPANDING LANDSCAPE
Srivastava, P., Wal, P., Chaturvedi, V., Wal, A., & Srivastava, A. (2022) · Journal of Population Therapeutics and Clinical Pharmacology · doi:10.53555/jptcp.v29i04.4372 · Cited by 1
Management of type 2 diabetes after metabolic bariatric surgery
Tham, K. W., & Lee, P. C. (2023) · Mini-invasive Surgery · doi:10.20517/2574-1225.2023.80 · Cited by 1
Emerging glucagon-based therapies in diabetes mellitus: Toward a better future in diabetes care
Gnanathayalan, S. W., & Sumanatilleke, M. (2024) · Journal of Diabetology · doi:10.4103/jod.jod_110_23
Dual GIP and GLP-1 agonists and changes in the lipid spectrum
Karásek, D. (2024) · Vnitřní lékařství · doi:10.36290/vnl.2024.006
Traiter les hypoglycémies iatrogènes à l’ère des nouvelles technologies
Monnier, L., & Colette, C. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.02.002
Outcomes of Type 2 Diabetes Management: One Center Experience 2015–2023
Chlup, R., Zálešáková, H., Gottwaldová, J., Trefil, M., Zapletalová, J., Kaňa, R., Hanáčková, L., Bretšnajdrová, M., Falt, P., & Polzerová, Z. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1005206
Approche thérapeutique de l’obésité via la restriction calorique traditionnelle
Monnier, L., Colette, C., Azrak, A. E., Essekkat, N., Bakri, A., & Rochd, D. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.11.006
A GLP-1-receptoragonistákon túl – az elhízás modern kezelési lehetőségei
Sztanek, F., & Tóth, L. I. (2024) · Diabetologia Hungarica · doi:10.24121/dh.2024.17
Medical management of obesity: unlocking the potential
Xiang, A. S., & Sumithran, P. (2025) · Climacteric · doi:10.1080/13697137.2025.2455177
“…from its additional effects, which include inhibiting accumulation of liver fat, promoting satiety and increasing whole-body energy expenditure [18]. in a phase 2 trial, retatrutide, a triple agonist of GiP, GlP-1 and glucagon receptors, demonstrated weight loss surpassing all medical…”
Novel Peptides as GIPR/GLP-1R/GCGR Triagonists for Treating Type 2 Diabetes Mellitus
Hu, Q.-L., & Liang, S. H. (2025) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5c00435
Therapeutic advances in type 1 myotonic dystrophy complicated with type 2 diabetes mellitus
Luo, L., Zhu, C., Yang, S., Sun, Y., Rong, M., & Li, T. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1640563
“These combined effects contribute to blood glucose control and weight reduction (119, 139).”
Emerging Role Of Multifaceted Drugs In Diabetes Care
Chaudhari, J. B. (2025) · African Journal of Biomedical Research · doi:10.53555/ajbr.v27i6s.8507
Research Progress of GLP-1 Receptor Agonists in the Treatment of Alzheimer’s Disease
勾, 琳. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.15123625
Efficacy of Dual Glucagon and GLP-1 Agonists as New Treatments for Type II Diabetes
Vats, J., Chauhan, A., Rajput, S., Sridhar, S. B., Vashist, C., Mittal, A., & Malviya, R. (2026) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575419389251118100027
Nguyen, T., Leemberg, C., & Lee, K. L. (2026) · Bioscience Reports · doi:10.1042/bsr20250378
“New drug discoveries have often come from understanding the hormones involved in glucose metabolism [4,5].”
Kowalczyk, O., Zieba, A., Domin, M., Kowalska, M., Ścibisz, K., Całka, J., Zdobylak, D., Ollik, K., Harenza, K., & Taranowicz, M. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.5160
Zheng, X., Xu, Q., Wei, Y., Chen, F., Li, G., Yu, S., & Ge, J. (2026) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2026.117866
The role of metabolic disorders in major depressive disorder
Sun, L., Qin, Y., Fan, X., Chen, J. K., & Du, L. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-11969-7
“Furthermore, common gastrointestinal side effects could reduce treat - ment adherence, especially in patients already experiencing somatic depressive symptoms [81].”
The emerging role of branched-chain amino acid metabolism in obesity
Wang, D., Wang, X., & Yang, M. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02103-5
“Mixtures of peptides as well as long-acting single-molecule mono-, dual-, and multi-agonists have been developed to interact with receptors for GLP-1, GIP, glucagon, amylin, and other peptides [123].”
Withrow, N. A., Hsueh, E. E., Wolever, T., Jenkins, A. L., Campbell, J. C., Zurbau, A., McMahon, R., & Valentine, C. J. (2026) · Current Developments in Nutrition · doi:10.1016/j.cdnut.2026.109393
Gautam, R., Wang, H., Zhou, B., Neba, R. A., & Sambamoorthi, U. (2026) · Alcohol and Alcoholism · doi:10.1093/alcalc/agag045
Kwon, W. Y., Moon, Y., Jung, S. W., Kim, Y. G., Lee, S. H., Moon, M. K., Jung, G. T., Kim, K. P., Lee, T. H., & Moon, J.-Y. (2026) · Journal of Analytical Science & Technology · doi:10.1186/s40543-026-00557-w · Cited by 1
“GLP-1RA induces delayed gastric emptying, inhibits post-meal glucagon release, and reduces food intake (Tschöp et al. 2023).”
Brunetti, K., Fassari, B., Catalani, E., Galletti, G., Quondam, S. D., Mocciaro, E., Giovarelli, M., Palma, C. D., Perrotta, C., Clementi, E., et al. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119735
Histoire des incrétines GLP-1/GIP – De l’hormone au médicament couteau-suisse
Portha, B. (2026) · Biologie Aujourd hui · doi:10.1051/jbio/2026005
Zajdenverg, L., Santos, V. M., Rodrigues, A. C. M., Previdelli, L. K., & Negrato, C. A. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02235-8
Sharma, A., Lee-Ødegård, S., Holst, J. J., Hartmann, B., Kvist, A. A. S., Qvigstad, E., Sollid, S. T., Nermoen, I., & Birkeland, K. I. (2026) · Diabetologia · doi:10.1007/s00125-026-06898-w
Dose-response profiles in incretin and multi-agonist obesity pharmacotherapy
Yousefian, M., & Baharmast, M. (2026) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2026.102947
Metadata
- Authors
- Tschöp, M., Nogueiras, R., & Ahrén, B.
- Affiliations
- Helmholtz Munich (DE)
- Venue
- Diabetologia
- Published
- 2023-05-20
- Volume
- 66
- Issue
- 10
- Pages
- 1796-1808
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- PMC
- PMC10474213
- OpenAlex
- W4377138246
- Cited by
- 92
- References
- 105
- Citations by year
- 2026: 23 · 2025: 23 · 2024: 33 · 2023: 12
- FWCI
- 3.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Diabetologia (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RUNA. Repositorio Institucional del Sergas (Servicio Gallego de Salud (SERGAS)) (submittedVersion, cc-by)
- Lund University Publications (Lund University) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
- Funders
- Medicinska Fakulteten, Lunds Universitet (314314)
- Lund University
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- GLP-1 receptor agonists, gastrointestinal hormones, type 2 diabetes, obesity, DPP-4 inhibitors, exendin-4, GIP/GLP-1 receptor agonist, insulin secretion, satiety, beta-cell function, energy expenditure, drug formulation
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Body Weight, Diabetes Mellitus, Type 2, Glucagon, Glucose, Humans, Obesity, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.